Table 2. Inflammatory/autoimmune rheumatic and musculoskeletal disease activity and medications.
IJDn=5207 | CTDn=1320 | Vasculitisn=686 | OIRMDn=123 | All patientsn=7336 | |
Physician-reported disease activity | |||||
Remission | 1934 (37.1) | 526 39.8) | 393 (57.3) | 62 (50.4) | 2915 (39.7) |
Low disease activity | 1487 (28.6) | 304 (23) | 180 (26.2) | 40 (32.5) | 2011 (27.4) |
Moderate disease activity | 808 (15.5) | 74 (5.6) | 47 (6.9) | 9 (7.3) | 938 (12.8) |
High disease activity | 147 (2.8) | 12 (0.9) | 8 (1.2) | 1 (0.8) | 168 (2.3) |
Missing/unknown | 831 (16) | 404 (30.6) | 58 (8.4) | 11 (9) | 1304 (17.8) |
Antirheumatic medication exposure | |||||
csDMARDs | 3289 (63.2) | 786 (59.6) | 163 (23.8) | 31 (25.2) | 4269 (58.2) |
Antimalarials | 323 (6.2) | 632 (47.9) | 11 (1.6) | 8 (6.5) | 974 (13.3) |
Held before vaccination | 1 | 1 | 0 | 0 | 2 |
Reduced before vaccination | 0 | 1 | 0 | 0 | 1 |
Held after vaccination | 1 | 2 | 0 | 0 | 3 |
Reduced after vaccination | 0 | 2 | 0 | 0 | 2 |
Leflunomide | 379 (7.3) | 14 (1.1) | 9 (1.3) | 1 (<1) | 403 (5.5) |
Held before vaccination | 6 | 0 | 0 | 0 | 6 |
Reduced before vaccination | 1 | 0 | 0 | 0 | 1 |
Held after vaccination | 2 | 0 | 0 | 0 | 2 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Methotrexate | 2200 (42.3) | 139 (10.5) | 141 (20.6) | 22 (17.9) | 2502 (34.1) |
Held before vaccination | 66 | 3 | 5 | 0 | 74 |
Reduced before vaccination | 10 | 0 | 1 | 0 | 11 |
Held after vaccination | 137 | 6 | 7 | 1 | 151 |
Reduced after vaccination | 6 | 0 | 0 | 0 | 6 |
Sulfasalazine | 387 (7.4) | 1 (<1) | 2 (<1) | 0 | 390 (5.3) |
Held before vaccination | 1 | 0 | 0 | 0 | 1 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 1 | 0 | 0 | 0 | 1 |
bDMARDs | 3042 (58.4) | 130 (9.8) | 146 (21.3) | 31 (25.2) | 3349 (45.7) |
Abatacept | 118 (2.3) | 2 (<1) | 1 (<1) | 0 | 121 (1.6) |
Held before vaccination | 6 | 0 | 0 | 0 | 6 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 3 | 0 | 0 | 0 | 3 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Belimumab | 0 | 38 (2.9) | 0 | 0 | 38 (<1) |
Held before vaccination | 0 | 2 | 0 | 0 | 2 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Rituximab | 187 (3.6) | 71 (5.4) | 57 (8.3) | 6 (4.9) | 321 (4.4) |
Held before vaccination | 14 | 1 | 7 | 2 | 24 |
Reduced before vaccination | 1 | 0 | 0 | 1 | 2 |
Held after vaccination | 1 | 1 | 0 | 0 | 2 |
Reduced after vaccination | 1 | 0 | 0 | 0 | 1 |
IL-1 inhibitors | 19 (<1) | 2 (<1) | 1 (<1) | 7 (5.7) | 29 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
IL-6 inhibitors | 278 (5.3) | 9 (<1) | 63 (9.2) | 3 (2.4) | 353 (4.8) |
Held before vaccination | 13 | 1 | 3 | 0 | 17 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 9 | 0 | 0 | 0 | 9 |
Reduced after vaccination | 1 | 0 | 0 | 0 | 1 |
IL-12/23 inhibitors | 46 (<1) | 2 (<1) | 1 (<1) | 0 | 49 (<1) |
Held before vaccination | 1 | 0 | 1 | 0 | 2 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
IL-23 inhibitors | 6 (<1) | 0 | 0 | 0 | 6 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
IL-17 inhibitors | 207 (4.2) | 1 (<1) | 0 | 1 (<1) | 209 (2.8) |
Held before vaccination | 5 | 0 | 0 | 0 | 5 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 5 | 0 | 0 | 0 | 5 |
Reduced after vaccination | 1 | 0 | 0 | 0 | 1 |
TNF inhibitors | 2181 (41.9) | 5 (<1) | 23 (3.4) | 14 (11.4) | 2223 (30.3) |
Held before vaccination | 67 | 0 | 2 | 0 | 69 |
Reduced before vaccination | 9 | 0 | 0 | 0 | 9 |
Held after vaccination | 58 | 1 | 1 | 0 | 60 |
Reduced after vaccination | 5 | 0 | 0 | 0 | 5 |
tsDMARDs | 241 (4.6) | 7 (<1) | 1 (<1) | 0 | 249 (3.4) |
Apremilast | 13 (<1) | 0 | 0 | 0 | 13 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
JAK inhibitors | 228 (4.4) | 7 (<1) | 1 (<1) | 0 | 236 (3.2) |
Held before vaccination | 7 | 0 | 0 | 0 | 7 |
Reduced before vaccination | 2 | 0 | 0 | 0 | 2 |
Held after vaccination | 26 | 1 | 0 | 0 | 27 |
Reduced after vaccination | 2 | 0 | 0 | 0 | 2 |
Immunosuppressants | 1294 (24.9) | 729 (55.2) | 495 (72.2) | 63 (51.2) | 2581 (35.2) |
Glucocorticoids (systemic) | 1255 (24.1) | 463 (35.1) | 447 (65.2) | 56 (45.5) | 2221 (30.3) |
Held before vaccination | 2 | 2 | 2 | 0 | 6 |
Reduced before vaccination | 3 | 1 | 2 | 0 | 6 |
Held after vaccination | 4 | 0 | 2 | 0 | 6 |
Reduced after vaccination | 1 | 0 | 7 | 0 | 8 |
Azathioprine/6-mercaptopurine | 19 (<1) | 94 (7.1) | 32 (4.7) | 4 (3.3) | 149 (2) |
Held before vaccination | 0 | 2 | 0 | 1 | 3 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 1 | 0 | 0 | 1 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Ciclosporin | 12 (<1) | 17 (1.3) | 0 | 0 | 29 (<1) |
Held before vaccination | 1 | 1 | 0 | 0 | 2 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Cyclophosphamide | 1 (<1) | 7 (<1) | 5 (<1) | 0 | 13 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Mycophenolate mofetil/mycophenolic acid | 5 (<1) | 142 (10.8) | 11 (1.6) | 3 (2.4) | 161 (2.2) |
Held before vaccination | 1 | 4 | 0 | 0 | 5 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 3 | 0 | 0 | 3 |
Reduced after vaccination | 0 | 1 | 0 | 0 | 1 |
Tacrolimus | 2 (<1) | 6 (<1) | 0 | 0 | 8 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Other medications | |||||
Intravenous immunoglobulin | 1 (<1) | 12 (<1) | 2 (<1) | 1 (<1) | 16 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 1 | 0 | 0 | 1 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
Antifibrotics | 8 (<1) | 2 (<1) | 0 | 0 | 10 (<1) |
Held before vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced before vaccination | 0 | 0 | 0 | 0 | 0 |
Held after vaccination | 0 | 0 | 0 | 0 | 0 |
Reduced after vaccination | 0 | 0 | 0 | 0 | 0 |
No DMARD therapy | 201 (3.9) | 224 (17) | 71 (10.3) | 20 (16.3) | 516 (7) |
Unknown | 46 (<1) | 37 (2.8) | 3 (<1) | 1 (<1) | 87 (1.2) |
All medications including monotherapy and/or combination therapy.
bDMARDsbiological DMARDscsDMARDsconventional synthetic DMARDsCTDconnective tissue diseaseDMARDdisease-modifying antirheumatic drugIJDinflammatory joint diseaseILinterleukinJAKJanus kinaseOIRMDother inflammatory rheumatic and musculoskeletal diseaseTNFtumour necrosis factortsDMARDstargeted synthetic DMARDs